DBV Technologies 주식 가격. DBV - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

가격

0.813

매수가

0.812

매도가

0.819

거래량

68,038

0.81 일간 변동폭 0.827

0.506 52주 범위 1.676

market_cap

76.542M

전일 종가

0.822

개장가

0.82

최근 거래 시간

618

0.813

마지막 거래 시간

20:04:09

재정 규모

VWAP

평균 볼륨(3m)

833,994

발행 주식

94,147,319

배당수익률

주가수익률

0.00

주당순이익(EPS)

매출

15.73M

순이익

-72.71M

섹터

Pharmaceutical Preparations

산업

Pharmaceutical Preparations

웹사이트

www.dbv-technologies.com

본부

Chatillon, Hauts-de-seine, Fra

설립됨

DBV Technologies is listed in the Pharmaceutical Preparations sector of the 유로넥스트 (Euronext) with ticker DBV. The last closing price for DBV Technologies was 0.82 €. Over the last year, DBV Technologies shares have traded in a share price range of 0.506 € to 1.676 €.

DBV Technologies currently has 94,147,319 shares in issue. The market capitalisation of DBV Technologies is 77.39 € million.

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF AMF Regulated InformationChâtillon, France, January 13, 2025 Half-Year...

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF Informations RéglementéesChâtillon, France, le 13 janvier 2025 Bilan...

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated InformationChâtillon, France, January 13, 2025 Half-Year Report on the DBV Technologies...

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study Châtillon, France, January 8th, 2025 DBV...

DBV Technologies présente les résultats positifs à 3 ans de l'étude de prolongation en ouvert d 'EPITOPE, étude clinique de phase 3

DBV Technologies présente les résultats positifs à 3 ans de l'étude de prolongation en ouvert d 'EPITOPE, étude clinique de phase 3...

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

Châtillon, France, January 8th, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3...

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old Châtillon, France...

DBV confirme l’alignement avec la FDA (US) sur la procédure d'approbation accélérée du patch Viaskin® Peanut chez les enfants âgés de 1 à 3 ans

DBV confirme l’alignement avec la FDA (US) sur la procédure d'approbation accélérée du patch Viaskin® Peanut chez les enfants âgés de 1 à 3...

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway...

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024 ...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0.009	1.11940298507	0.804	0.89	0.78	379023	0.81814636	DE
4	-0.074	-8.34272829763	0.887	0.97	0.76	413352	0.84291162	DE
12	0.263	47.8181818182	0.55	1.16	0.52	833994	0.81215152	DE
26	-0.057	-6.55172413793	0.87	1.47	0.506	502750	0.80712634	DE
52	-0.854	-51.2297540492	1.667	1.676	0.506	301680	0.86714903	DE
156	-1.832	-69.2627599244	2.645	5.48	0.506	215877	2.08214602	DE
260	-16.687	-95.3542857143	17.5	18.27	0.506	365955	5.03062824	DE

DBV - Frequently Asked Questions (FAQ)

What is the current DBV Technologies share price?

The current share price of DBV Technologies is 0.813 €

How many DBV Technologies shares are in issue?

DBV Technologies has 94,147,319 shares in issue

What is the market cap of DBV Technologies?

The market capitalisation of DBV Technologies is EUR 77.39M

What is the 1 year trading range for DBV Technologies share price?

DBV Technologies has traded in the range of 0.506 € to 1.676 € during the past year

What is the reporting currency for DBV Technologies?

DBV Technologies reports financial results in USD

What is the latest annual turnover for DBV Technologies?

The latest annual turnover of DBV Technologies is USD 15.73M

What is the latest annual profit for DBV Technologies?

The latest annual profit of DBV Technologies is USD -72.71M

What is the registered address of DBV Technologies?

The registered address for DBV Technologies is 107 AVENUE DE LA REPUBLIQUE, CHATILLON, HAUTS-DE-SEINE, 92120

What is the DBV Technologies website address?

The website address for DBV Technologies is www.dbv-technologies.com

Which industry sector does DBV Technologies operate in?

DBV Technologies operates in the PHARMACEUTICAL PREPARATIONS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
ALCYBCybergun	0.0002 € (100.00%)	28.4M
ALEUPEuroplasma	0.0143 € (41.58%)	32.53M
YOUNIYounited Financial SA	17.00 € (30.77%)	150
ALALOAcheterLouerFR	0.0091 € (22.97%)	6.88M
MLLOILocasystem International	13.50 € (20.54%)	2
MLSMLSmalto	0.014 € (-30.00%)	36k
ALNEVNeovacs	0.0998 € (-20.16%)	43.92k
MLSEQSequa Petroleum NV	0.008 € (-20.00%)	2.5k
ALVERVergnet	0.0005 € (-16.67%)	23.16M
ALVGVEOM Group	0.323 € (-14.10%)	39.49k
ATOAtos SE	0.0029 € (7.41%)	2.41B
BCPBanco Comercial Portugues SA	0.5408 € (1.58%)	37.93M
ALEUPEuroplasma	0.0143 € (41.58%)	32.53M
ALCYBCybergun	0.0002 € (100.00%)	28.4M
ALVERVergnet	0.0005 € (-16.67%)	23.16M

misterfishman 5 분 전

Hahahaha ok bro.

RDAR

misterfishman 6 분 전

Sorry you don't post everyday I didn't know who you were but over 70 mill shares is impressive and I tip my hat too you well done indeed you are a true gambler very impressive.

RDAR

PegnVA 6 분 전

More money probably wouldn't be worth working at the whim of the unstable convicted felon in the Oval - engineers with valuable experience can command good pay in the private sector.

theorysuit 11 분 전

Hmm lot of effort and jibberish to silence this tells me the paid pump crew knows this is damaging......

15m burn will go up if they intend to commercialize and run new trials but I guess that is not fact based.....lmfao.

NWBO

sab63090 13 분 전

Vinmatoo:

NPR is a liberal oriented organization....you know this surely!

I think most people will be able to handle this Flu Season and COVID also.

I did receive my flu shot in case you were wondering.

MasterBlastr 15 분 전

Intents and purposes.

PegnVA 16 분 전

Well I would hope so.

RSI38 17 분 전

Agreed 👍

If he is here he admitting it's not dead

Se you in May of this year

NPHC

NPHC

sctts 19 분 전

$$$ Today is the Day $$$$

$$$$ $FRX $$$

FRX

RichieBoy 20 분 전

GROK reflects on it's own errors to reach a logical consistency. More speed cracking the code on the assignment and less human interaction finding right path going forward ON IT'S OWN.

THINK of the time saven finding curative solutions to diseases or best case forward on new construct

AFFU

dmb2 27 분 전

eagle8, I think it is fair to say, based on the scientific and mfg technical advances by NWBO, that we have witnessed their vision advanced to a strategy, progressed to a plan and is now in project timetable form with discrete steps to take a singular therapy for GBM (a major oncology breakthrough)

NWBO

SkeBallLarry 31 분 전

Thanks Bull ~ and more precip coming Tues-Weds .. !!

Bull_Dolphin 34 분 전

I hope it isn't true, but Musk tweeting about it doesn't look good. We shall see.

Newtogame 36 분 전

LOL Well that was a mess !!!!!!

SkeBallLarry 37 분 전

" That is sad news " .. !!!

BottomBounce 39 분 전

Fed Chair Jerome Powell asserted Tuesday that the central bank will not develop its own digital currency as long as he is in charge, ending several years of speculation https://cnbc.com/2025/02/11/powell-squashes-the-possibility-that-the-fed-will-develop-its-own-digital-currency.html $MSTR

MSTR

BottomBounce 39 분 전

COIN

BottomBounce 40 분 전

Gold and Silver bullion prices are on fire today.. Solidity they are up like Bitcoin was when it was $3000 $GLD $PLSV

GLD PLSV

BottomBounce 41 분 전

Gold and Silver bullion prices are on fire today.. Solidity they are up like Bitcoin was when it was $3000

Nelson2 42 분 전

https://stocks.apple.com/AyIBBAScpSJuNuV0V0P45JQ

GLTA

BTCS

BottomBounce 43 분 전

Precious Metals EXPLODE on DOGE findings of massive debt, hidden payments all over the world.

BottomBounce 43 분 전

Precious Metals EXPLODE on DOGE findings of massive debt, hidden payments all over the world.

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

DBV Technologies (DBV)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

DBV Technologies 정보

DBV 최신 뉴스

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

DBV Technologies présente les résultats positifs à 3 ans de l'étude de prolongation en ouvert d 'EPITOPE, étude clinique de phase 3

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

DBV confirme l’alignement avec la FDA (US) sur la procédure d'approbation accélérée du patch Viaskin® Peanut chez les enfants âgés de 1 à 3 ans

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF

DBV Technologies présente les résultats positifs à 3 ans de l'étude de prolongation en ouvert d 'EPITOPE, étude clinique de phase 3

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

DBV - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

DBV Technologies (DBV) 시세

DBV Technologies (DBV)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

DBV Technologies 정보

DBV 최신 뉴스

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

DBV Technologies présente les résultats positifs à 3 ans de l'étude de prolongation en ouvert d 'EPITOPE, étude clinique de phase 3

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

DBV confirme l’alignement avec la FDA (US) sur la procédure d'approbation accélérée du patch Viaskin® Peanut chez les enfants âgés de 1 à 3 ans

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF

DBV Technologies présente les résultats positifs à 3 ans de l'étude de prolongation en ouvert d 'EPITOPE, étude clinique de phase 3

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

DBV - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거